US Drug Recall Register

FDA Drug Recalls

1,709 recalls · Class III, newest first

Class III · Low risk Terminated

Fentanyl Buccal Tablets CII

Reason Labeling: Incorrect or Missing Package Insert

Teva Pharmaceuticals USA Inc NDC 51862-634-28 D-0766-2023
Class III · Low risk Terminated

Gabapentin Tablets

Reason Product mixup: one foreign tablet found in product.

The Harvard Drug Group NDC 0904-6823-61 D-0570-2023
Class III · Low risk Ongoing

Lidocaine Patch 5%

Reason Labeling: Typographical error on the upper left-hand side of the box and individual patch label that has the incorrect dosage form stating, each tablet contains instead of each adhesive patch contains.

Bryant Ranch Prepack, Inc. D-0556-2023
Class III · Low risk Terminated

Avicel DG

Reason Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

DuPont Nutrition USA, Inc D-0547-2023
Class III · Low risk Terminated

Avicel PH-200 NF

Reason Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

DuPont Nutrition USA, Inc D-0546-2023
Class III · Low risk Terminated

Avicel PH-102 NF

Reason Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

DuPont Nutrition USA, Inc D-0545-2023
Class III · Low risk Terminated

Avicel PH-101 NF

Reason Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

DuPont Nutrition USA, Inc D-0544-2023
Class III · Low risk Terminated

Norepinephrine Bitartrate Injection

Reason Failed Impurities/Degradation Specifications: Above the specification limits yielded for related substance norepinephrine sulfonic acid impurity during routine product monitoring.

Sun Pharmaceutical Industries INC NDC 47335-615-40 D-0529-2023
Class III · Low risk Terminated

Dodex Injectable Cyanocobalamin Injection

Reason Sub-potent drug: assay test result below specifications at 9-month timepoint.

Accord Healthcare, Inc. NDC 16729-533-08 D-0528-2023
Class III · Low risk Terminated

Bevacizumab 2.5 mg/0.1 mL

Reason Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.

Pine Pharmaceuticals, LLC NDC 69194-0458-1 D-0531-2023
Class III · Low risk Terminated

Montelukast Sodium Oral Granules USP

Reason Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

Teva Pharmaceuticals USA Inc NDC 0093-7487-56 D-0510-2023
Class III · Low risk Ongoing

Epinephrine Professional EMS

Reason Labeling; Incorrect NDC number on outer carton of product.

Focus Health Group Inc D-0535-2023
Class III · Low risk Terminated

Dofetilide Capsules

Reason Failed Content Uniformity Specifications

Sun Pharmaceutical Industries INC NDC 47335-0063-86 D-0474-2023
Class III · Low risk Ongoing

Mektovi

Reason Labeling: Incorrect or Missing Lot and/or Exp Date: The carton and bottle labels state an expiry date of March 2026; the correct expiration date is February 2025.

Pfizer Inc. D-0532-2023
Class III · Low risk Terminated

Colchicine Tablets

Reason Failed Impurities/Degradation Specifications: An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e. Beta-lumicolchicine.

Zydus Pharmaceuticals (USA) Inc NDC 16714-0039-01 D-0467-2023
Class III · Low risk Terminated

Fentanyl 1

Reason Subpotent Drug

SCA Pharmaceuticals NDC 70004-0200-16 D-0363-2023
Class III · Low risk Ongoing

Evamist

Reason Failed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability time point.

Padagis US LLC D-0464-2023
Class III · Low risk Terminated

Dibucaine 1% Hemorrhoidal Ointment

Reason Labeling: Incorrect or Missing Lot and/or Exp Date

Akron Pharma, Inc. NDC 71399-2829-1 D-0454-2023
Class III · Low risk Terminated

Gabapentin Tablets

Reason Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

Sciegen Pharmaceuticals Inc D-0354-2023
Class III · Low risk Terminated

Buprenorphine Transdermal System

Reason Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.

AVEVA Drug Delivery Systems, Inc. NDC 60505-7079-05 D-0466-2023
Class III · Low risk Terminated

Buprenorphine Transdermal System

Reason Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.

AVEVA Drug Delivery Systems, Inc. NDC 60505-7077-05 D-0465-2023
Class III · Low risk Terminated

Dermoplast FIRST AID ANTIBACTERIAL SPRAY

Reason Subpotent Drug: Low assay observed in one of the two active ingredients during stability testing.

Advantice Health, Llc NDC 16864-670-01 D-0329-2023
Class III · Low risk Terminated

Bd-102 Nf

Reason Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

DuPont Nutrition USA, Inc D-0352-2023
Class III · Low risk Terminated

Avicel PH-200 NF

Reason Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

DuPont Nutrition USA, Inc D-0351-2023